CEL-SCI Resultados de beneficios anteriores
Pasado controles de criterios 0/6
CEL-SCI's earnings have been declining at an average annual rate of -2.2%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 72.6% per year.
Información clave
-2.2%
Tasa de crecimiento de los beneficios
6.1%
Tasa de crecimiento del BPA
Crecimiento de la industria Biotechs | 17.0% |
Tasa de crecimiento de los ingresos | -72.6% |
Rentabilidad financiera | -343.5% |
Margen neto | n/a |
Última actualización de beneficios | 30 Jun 2024 |
Actualizaciones de resultados anteriores recientes
Desglose de ingresos y gastos
Cómo gana y gasta dinero CEL-SCI. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
30 Jun 24 | 0 | -29 | 9 | 0 |
31 Mar 24 | 0 | -30 | 9 | 0 |
31 Dec 23 | 0 | -31 | 9 | 0 |
30 Sep 23 | 0 | -32 | 9 | 0 |
30 Jun 23 | 0 | -34 | 9 | 0 |
31 Mar 23 | 0 | -35 | 9 | 0 |
31 Dec 22 | 0 | -37 | 10 | 0 |
30 Sep 22 | 0 | -38 | 11 | 0 |
30 Jun 22 | 0 | -37 | 11 | 0 |
31 Mar 22 | 0 | -36 | 12 | 0 |
31 Dec 21 | 0 | -37 | 13 | 0 |
30 Sep 21 | 0 | -37 | 13 | 0 |
30 Jun 21 | 0 | -34 | 13 | 0 |
31 Mar 21 | 0 | -35 | 13 | 0 |
31 Dec 20 | 1 | -33 | 12 | 0 |
30 Sep 20 | 1 | -30 | 12 | 0 |
30 Jun 20 | 1 | -30 | 11 | 0 |
31 Mar 20 | 1 | -32 | 10 | 0 |
31 Dec 19 | 0 | -29 | 9 | 0 |
30 Sep 19 | 0 | -22 | 8 | 0 |
30 Jun 19 | 1 | -32 | 6 | 0 |
31 Mar 19 | 1 | -26 | 6 | 0 |
31 Dec 18 | 1 | -24 | 5 | 0 |
30 Sep 18 | 0 | -32 | 6 | 0 |
30 Jun 18 | 0 | -22 | 7 | 0 |
31 Mar 18 | 0 | -20 | 7 | 0 |
31 Dec 17 | 0 | -24 | 7 | 0 |
30 Sep 17 | 0 | -14 | 6 | 0 |
30 Jun 17 | 0 | -10 | 8 | 0 |
31 Mar 17 | 0 | -10 | 8 | 0 |
31 Dec 16 | 0 | -10 | 7 | 0 |
30 Sep 16 | 0 | -12 | 8 | 0 |
30 Jun 16 | 0 | -20 | 7 | 0 |
31 Mar 16 | 0 | -21 | 8 | 0 |
31 Dec 15 | 1 | -25 | 10 | 0 |
30 Sep 15 | 1 | -35 | 14 | 0 |
30 Jun 15 | 1 | -32 | 15 | 0 |
31 Mar 15 | 0 | -30 | 15 | 0 |
31 Dec 14 | 0 | -31 | 14 | 0 |
30 Sep 14 | 0 | -28 | 11 | 0 |
30 Jun 14 | 0 | -23 | 8 | 0 |
31 Mar 14 | 0 | -25 | 7 | -5 |
31 Dec 13 | 0 | -12 | 7 | 0 |
Ingresos de calidad: CVM is currently unprofitable.
Margen de beneficios creciente: CVM is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: CVM is unprofitable, and losses have increased over the past 5 years at a rate of 2.2% per year.
Acelerando crecimiento: Unable to compare CVM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: CVM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rentabilidad financiera
Alta ROE: CVM has a negative Return on Equity (-343.45%), as it is currently unprofitable.